Format

Send to

Choose Destination
Platelets. 2019 Mar 5:1-9. doi: 10.1080/09537104.2019.1581922. [Epub ahead of print]

Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.

Author information

1
a Coagulation Disorders Unit, Department of Clinical Chemistry , HUSLAB Laboratory Services, Helsinki University Hospital , Helsinki , Finland.
2
b Faculty of Medicine , University of Helsinki , Helsinki , Finland.
3
c Coagulation Disorders Unit, Department of Hematology and Comprehensive Cancer Center and Research Program of Oncology , Helsinki University Hospital , Helsinki , Finland.
4
d Research Institute , Helsinki University Hospital , Helsinki , Finland.
5
e Department of Molecular and Cellular Hemostasis , Sanquin Research , Amsterdam , The Netherlands.

Abstract

In type 3 von Willebrand disease (VWD3), the most severe form with absent von Willebrand factor (VWF), the bleeding phenotype is variable. Platelet contribution to the hemostatic defect in VWD3 calls upon further studies. We investigated the contribution of platelets to in vitro thrombin generation (TG) and platelet procoagulant activity in VWD3. TG was assessed by calibrated automated thrombogram (CAT) in platelet-poor (PPP) and -rich plasma (PRP) from 9 patients before and in 6 patients also 30 min after receiving their regular VWF therapy. Responsiveness of PPP to FVIII and protein S was also investigated. TG data were compared with routine laboratory variables, rotational thromboelastometry (ROTEM) and platelet expression of P-selectin and phosphatidylserine in flow cytometry. Compared with healthy controls, TG was markedly decreased in VWD3 PPP (peak thrombin was 16% of normal median), but not in PRP (77% of normal median) (p = 0.002). Six out of nine patients (67%) were high responders in their platelet P-selectin, and 5/9 (56%) in phosphatidylserine expression. Replacement therapy improved TG in PPP, while in PRP TG only modestly increased or was unaffected. In PPP, FVIII levels associated with TG and in vitro FVIII-supplemented TG inclined up to threefold. Conversely, a FVIII inhibitory antibody reduced plasma TG in all, but especially in patients with remnant FVIII levels. Inhibition of protein S improved plasma TG, particularly at low FVIII levels. ROTEM failed to detect VWD3. In VWD3, TG is reduced in PPP and regulated by FVIII and protein S, but TG is close to normal in PRP. VWD3 platelets seem to compensate for the FVIII-associated reduction in TG by their exposure of P-selectin and phosphatidylserine.

KEYWORDS:

FVIII; platelet procoagulant activity; protein S; thrombin generation; von Willebrand disease type 3; von Willebrand factor

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center